Tempest Therapeutics license adds in vivo CAR-T candidates targeting blood cancers, solid tumors and autoimmune conditions

Observed price moves

• TPST+1.29%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.